Drug Transporter and Metabolizing Enzyme Gene Variants and Nonnucleoside Reverse-Transcriptase Inhibitor Hepatotoxicity
Open Access
- 15 September 2006
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 43 (6) , 779-782
- https://doi.org/10.1086/507101
Abstract
This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy withKeywords
This publication has 13 references indexed in Scilit:
- Multifactor dimensionality reduction: An analysis strategy for modelling and detecting gene - gene interactions in human genetics and pharmacogenomics studiesHuman Genomics, 2006
- Pharmacogenetics of Long‐Term Responses to Antiretroviral Regimens Containing Efavirenz and/or Nelfinavir: An Adult AIDS Clinical Trials Group StudyThe Journal of Infectious Diseases, 2005
- Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individualsClinical Pharmacology & Therapeutics, 2005
- Appropriate Use of Nevirapinefor Long‐Term TherapyThe Journal of Infectious Diseases, 2005
- Severe Hepatotoxicity Associated with Nevirapine Use in HIV‐Infected SubjectsThe Journal of Infectious Diseases, 2005
- Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patientsPharmacogenetics and Genomics, 2005
- Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevanceClinical Pharmacology & Therapeutics, 2004
- Multifactor dimensionality reduction software for detecting gene–gene and gene–environment interactionsBioinformatics, 2003
- Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture.Pharmaceutical Research, 2002
- Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics studyThe Lancet, 2002